Medicare Paid $380 Million for Unused Organs

Hand placing a puzzle piece labeled Medicare — Photo: WIN12_ET / Shutterstock

Medicare’s organ-transplant payment rules split cleanly on paper—pay one way for the surgery itself and another way for the organ—but a federal audit shows that a conflict between program guidance and the statute pushed hundreds of millions of dollars into the wrong bucket, funding organs that never ended up in Medicare-covered transplants.

The Short Version

A federal Inspector General audit estimated Medicare paid about $380 million over six years for organs not transplanted into Medicare enrollees, driven by conflicting rules rather than isolated billing mistakes.
In a sample, transplant centers were reimbursed roughly $2.8 million for 55 organs that either went to non-Medicare recipients or were never transplanted at all.
The issue sits at the junction of two payment streams: the DRG for the transplant procedure and a separate reimbursement for organ acquisition costs.
This is part of a broader pattern: complex Medicare cost-reporting, contractor implementation, and recurring OIG findings when guidance drifts from statute.

What the audit actually established

The Department of Health and Human Services Office of Inspector General (OIG) examined certified transplant centers’ reporting of “Medicare usable organs” and the associated reimbursements for organ acquisition. Using a probability sample from 2017 through 2022, OIG found that Medicare reimbursed transplant centers for organs that were not ultimately used in Medicare-covered transplants and extrapolated an estimated $380 million in program-wide overpayments over six years. At ground level, the sample included 180 organs reported as Medicare-usable; for 55 of them—43 transplanted into non-Medicare patients and 12 not transplanted at all—Medicare nonetheless paid about $2.8 million in acquisition costs. Secondary reporting tracked these key findings, underscoring the scale and the policy driver behind the payments.

Two points matter for interpreting the headline number. First, the $380 million is an extrapolation from a sample; like any estimate, it inherits the sample’s design and error bounds. Second, the audit did not frame this as fraud. OIG’s title is explicit: the problem arose from conflict between Centers for Medicare & Medicaid Services (CMS) guidance and the Medicare statute—a structural mismatch that, when propagated through thousands of cost reports, can generate very real dollars at national scale.

How Medicare pays for transplants—and where the gears slipped

Medicare pays the hospital for the transplant procedure through the inpatient prospective payment system (IPPS) using an MS-DRG. Separately, it reimburses “reasonable and necessary” organ acquisition costs—donor evaluation, tissue typing, operating room time for procurement, and related overhead—that are not included in the DRG. Transplant centers develop standard acquisition charges and, via the Medicare cost report, allocate Medicare’s share of those costs to organs counted as “Medicare usable.” Guidance has long said the reasonable costs of procuring an organ are reimbursable when incurred for a Medicare-covered transplant, and the accounting is reconciled through cost reporting rather than claim-by-claim pricing.

According to OIG, the conflict arose because CMS guidance simultaneously told centers not to count certain organs as Medicare-usable while also instructing them to count organs “furnished to another OPO or CTC” as Medicare-usable—even when those organs did not land in Medicare beneficiaries. The statute, OIG argues, limits reimbursement to organs used in Medicare-covered transplants; therefore, counting organs ultimately used for non-Medicare recipients—or never transplanted—pushed costs onto Medicare that the law does not allow. In other words, the gears slipped at the definition of the denominator: what qualifies as a Medicare-usable organ for purposes of allocating costs.

Why this is not about fraud—and still matters

Everyone in this ecosystem acted within a labyrinth of written instructions. CMS’s own manuals and transmittals emphasize two separate payment components and a cost-reporting mechanism that pays Medicare’s share of acquisition costs, not a bespoke price per organ. Transplant centers followed that scaffolding; the OIG’s critique is that the scaffolding itself deviated from the statute’s limit. That distinction matters. It cautions against moralizing headlines and turns the conversation to governance: how to keep program guidance aligned with law in domains where accounting definitions drive billions of dollars and there is no claim-line adjudication to catch misclassifications in real time.

It matters financially because organ acquisition is costly. Spread across six years of national activity, modest definitional drift can aggregate to nine-figure exposure. It matters clinically because every dollar misallocated within the cost-report pool changes incentives at the margin—what gets counted, what gets pursued, and how promptly paperwork catches up to clinical reality. And it matters administratively because Medicare’s cost-report settlement process is where corrections should surface; if a definition is off, the entire allocation algorithm inherits the error until the rule is fixed.

The sampling estimate and what we don’t yet know

The $380 million estimate rests on a sample of organs and corresponding cost-report entries; it is not a census of every center or organ over the six-year window. OIG’s highlights describe the sample-level results, but public snippets do not unpack the sampling frame, confidence intervals, or the list of centers examined. Nor do they specify the extent to which later cost-report settlements or reopenings clawed back any of the identified amounts. Those are knowable facts—locked up in workpapers, settlement files, or follow-up actions—not unknowable mysteries. Their absence does not blunt the core finding, but it does bound what one can infer about concentration (a few outliers versus broad practice) and the net, after-recoupment fiscal effect. Secondary coverage properly emphasized the estimate’s origin in extrapolation rather than a line-by-line recount.

Equally, CMS’s formal response would illuminate whether the agency accepts OIG’s statutory reading, disputes the sampling, or defends the payments as consistent with then-operative guidance. That response is the hinge between diagnosis and reform: if CMS agrees, corrective instructions and settlements should follow; if it disagrees, expect a technical debate about statutory text, implementing regulations, and definitions like “furnished to” versus “used in.”

This problem has a history—and a playbook for fixing it

Organ acquisition accounting has attracted oversight before. OIG and the Provider Reimbursement Review Board have repeatedly parsed what belongs in organ acquisition cost centers, how to count “Medicare usable organs,” and how to apportion shared costs. The work plan behind this audit signals a nationwide project rather than a one-off inquiry, consistent with a Medicare-wide pattern: complex payment rules, reliance on intermediaries, and periodic findings that guidance drifted from statute or was applied inconsistently.

When these disputes surface, the durable fix typically arrives in three steps. First, reconcile law and guidance: publish clear, operative definitions that track the statute and close contradictions—particularly around when an organ can be counted as Medicare-usable for cost allocation. Second, correct the past: reopen cost reports where material, apply the clarified rules, and settle over- or under-payments through established mechanisms. Third, retool incentives and data: require transparent center-level reporting of organ disposition (Medicare, non-Medicare, not transplanted) that ties directly to the cost-report schedule used for acquisition cost allocation. None of this requires reinventing Medicare; it requires precision in the cost-report denominator and the data that feed it.

What stakeholders should watch next

Three developments will tell you whether this becomes a footnote or a genuine reform. Watch for CMS’s formal position on the OIG’s statutory reading; that will set the trajectory. Watch for technical transmittals or manual updates that reset the definition of “Medicare usable organ” to align with the statute; that is the operational fix that changes future dollars. And watch for settlement activity—reopenings, recoupments, or prospective adjustments in cost-report instructions—that convert an audit finding into budget reality. If those arrive, the $380 million becomes not just a cautionary tale but a resolved variance. If they don’t, expect the ambiguity to persist until litigated or legislated away.